The estimated Net Worth of Michael A. Panzara is at least $2.66 Million dollars as of 4 May 2022. Michael Panzara owns over 16,714 units of Wave Life Sciences stock worth over $643,708 and over the last 8 years he sold WVE stock worth over $743,873. In addition, he makes $1,272,000 as Chief Medical Officer at Wave Life Sciences.
Michael has made over 10 trades of the Wave Life Sciences stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 16,714 units of WVE stock worth $28,748 on 4 May 2022.
The largest trade he's ever made was exercising 18,750 units of Wave Life Sciences stock on 15 February 2018 worth over $406,688. On average, Michael trades about 3,590 units every 88 days since 2016. As of 4 May 2022 he still owns at least 109,103 units of Wave Life Sciences stock.
You can see the complete history of Michael Panzara stock trades at the bottom of the page.
Dr. Michael A. Panzara M.D. serves as Chief Medical Officer of the Company. serves as Chief Medical Officer of the Company. During the period July 2016 to October 2018, Dr. Panzara served as our Franchise Lead, Neurology. Prior to joining us, Dr. Panzara served in various roles at Sanofi Genzyme (and Genzyme Corporation before its merger with Sanofi in 2011) from 2009 to July 2016, most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr. Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011, Dr. Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998, and completed his post-doctoral training in immunology and rheumatology at Brigham and Women’s Hospital. Dr. Panzara holds a bachelor’s degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master’s degree in public health from the Harvard School of Public Health.
As the Chief Medical Officer of Wave Life Sciences, the total compensation of Michael Panzara at Wave Life Sciences is $1,272,000. There are 2 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.
Michael Panzara is 53, he's been the Chief Medical Officer of Wave Life Sciences since 2018. There are 8 older and 10 younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011.
Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ..., and Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Wave Life Sciences executives and other stock owners filed with the SEC include: